BACKGROUND
Little has been reported on the costs of managing the adverse events (AEs) associated with current therapies for patients with regional or distant metastatic melanoma.
OBJECTIVE
To identify treatment-related AEs in patients with metastatic melanoma and to estimate the associated costs of